FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma
FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma The ASCO Post
2026
FDA Approves Drug for Pancreatic Cancer in Milestone for Treatment of Deadly Disease
FDA Approves Drug for Pancreatic Cancer in Milestone for Treatment of Deadly Disease WSJ
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic…